RESEARCH INTERESTS: Immunotherapies to mediate allergy and asthma
905-525-9140 ext. 21284
Mark Larché is Canada Research Chair in Allergy & Immune Tolerance and Professor in the Department of Medicine at McMaster University. Larché is also Honorary Professorial Research Fellow in the Faculty of Medicine at Imperial College, London, UK from where he recently (Sept 2006) made the move to Canada. In 2004 he was a Distinguished Visiting Professor at the University of Manitoba, Canada. From 2001-2006 he was an Asthma UK Senior Research Fellow. He is a former member of the Medical Research Council New Investigator Awards (NIA) Panel, the MRC College of Experts (Physiological Systems and Clinical Sciences Board) and the Asthma UK Research Committee. He was Chairman of the Asthma Section of the European Academy of Allergology and Clinical Immunology (EAACI) from 2001-2005, a member of the EAACI Executive Committee (2001-2005) and a member of the BSI Vaccine Affinity Group Board (2003-2006). Larché is an Associate Editor of Respiratory Research and a member of the editorial board of Clinical Experimental Immunology and Clinical Experimental Allergy. He is a member of the AllerGen Network of Centres of Excellence and numerous professional societies including the Institute of Learning and Teaching, the British Society for Immunology, the British Society of Allergy and Clinical Immunology, the European Academy of Allergology and Clinical Immunology, the American Academy of Allergy, Asthma and Immunology, the Collegium Internationale Allergologicum. Together with Professor AB Kay, he founded “Circassia Ltd.”, a biotechnology company to develop vaccines for allergic diseases. Research interests extend beyond asthma and allergies into transplantation, coeliac disease and autoimmune diseases.
McMaster University, MDCL 4010
1280 Main Street West
Hamilton, ON, Canada
Monday to Friday
8:30am to 4:30pm
The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at email@example.com.